Analysis of Circulating Tumour DNA to Monitor Metastatic Breast Cancer

Google+ Pinterest LinkedIn Tumblr +

DNASARAH-JANE Dawson published a paper on the management of metastatic breast cancer in the NEJM, 13 March 2013. 

The management of metastatic breast cancer requires monitoring of the tumour burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumour cells have been widely studied.

However, circulating cell-free DNA carrying tumour-specific alterations (circulating tumour DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer…Read more

Source: http://www.nejm.org

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.